查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930079

全球液體活檢市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量、未來預測（2026-2034）

Liquid Biopsy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 155 Pages | 商品交期: 請詢問到貨日

價格

液體切片市場成長驅動因素

預計2025年全球液體切片市場規模將達到116.6億美元，2026年將成長至142.3億美元，到2034年將達到1064.9億美元。預計該市場在預測期內將以28.61%的複合年增長率成長。這種快速成長主要受癌症發病率上升、對非侵入性診斷技術的需求增加以及分子​​診斷技術進步的推動。

液體切片是指檢測和分析血液、腦脊髓液和羊水等生物體液中的循環腫瘤DNA (ctDNA)、遊離DNA (cfDNA)、循環腫瘤細胞和生物標記。這些檢測方法為癌症診斷、預後評估和治療方案選擇提供了一種微創替代方案，可取代傳統的組織活檢。

市場規模（依報告年份劃分的價值）

  • 市場規模（2025 年）：116.6 億美元
  • 市場規模（2026 年）：142.3 億美元
  • 市場規模（預測，2034 年）：1,064.9 億美元

主要成長驅動因素

全球癌症負擔日益加重是推動市場成長的主要因素。根據印度醫學研究理事會 (ICMR) 的數據，預計印度癌症病例數將從 2020 年的 139 萬例增加到 2022 年的 146 萬例，與全球趨勢一致。這一激增推動了對早期篩檢、疾病監測和精準腫瘤學解決方案的需求。

此外，由於唐氏症等染色體異常的盛行率不斷上升，液體活檢在非侵入性產前檢測 (NIPT) 中發揮重要作用。政府支持的篩檢計畫以及人們對早期疾病檢測意識的提高，進一步推動了液體活檢的普及。

美國食品藥物管理局 (FDA) 和其他機構對先進癌症檢測技術的監管批准，以及持續的臨床研究和技術創新，都極大地促進了市場擴張。

市場限制因子

儘管液體活檢具有諸多優勢，但其市場仍面臨著高昂的檢測成本和有限的報銷等挑戰。在美國，每次液體活檢的費用可能超過 2000 美元，使其難以用於常規篩檢。此外，報銷限制，尤其是在早期癌症篩檢方面，阻礙了液體活檢的更廣泛應用，尤其是在印度和中國等發展中國家。

市場區隔分析

依產品分類：

試劑盒和試劑佔市場主導地位，預計到 2026 年將佔市場佔有率的 80.08%，這主要得益於 ctDNA 和 NIPT 檢測產品的頻繁上市和批准。儀器預計將以適度的速度成長，這得益於 PCR 和 NGS 平台技術的進步。

依應用分類：

到 2026 年，非侵入性產前檢測 (NIPT) 將佔最大的市場佔有率，達到 68.69%，這主要得益於產前篩檢需求的成長。腫瘤學領域預計將以更高的複合年增長率成長，這主要得益於其在癌症診斷、治療監測和復發檢測等領域的應用不斷擴展。

依最終使用者劃分：

到 2026 年，醫院將佔市場主導地位，市佔率高達 75.01%。這主要得益於醫院龐大的患者群體以及癌症檢測和產前檢測的日益普及。臨床實驗室預計將因診斷基礎設施的擴展而實現顯著成長。

區域因素

預計到 2025 年，北美將引領全球液體活檢市場，市場佔有率達到 54.57%，這得益於強勁的研發投入、精準腫瘤學的早期應用以及有利的報銷機制。

歐洲緊隨其後，這主要得益於政府主導的癌症篩檢計畫以及對診斷技術創新投入的增加。

預計亞太地區將實現最快增長，這主要得益於癌症發病率的上升、醫療保健覆蓋範圍的擴大以及中國、日本和印度等國家無創胎兒染色體檢測 (NIPT) 的日益普及。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家癌症發生率（2025 年）
  • 主要產業趨勢：併購、業務合作
  • 主要公司新產品發布
  • 新冠疫情對市場的影響

第五章 全球液體切片市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品分類
    • 試劑盒及試劑
    • 設備
  • 市場分析、洞察與預測：依應用分類
    • 非侵入性產前檢測 (NIPT)
    • 腫瘤學
    • 其他
  • 市場分析、洞察與預測：依最終用戶分類
    • 醫院
    • 臨床實驗室
    • 其他
  • 市場分析、洞察與預測：依地區分類
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美液體切片市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲液體切片市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第八章 亞太地區液體切片市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 其他地區亞太地區

第九章：拉丁美洲液體切片市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲液體切片市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）成員國
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
    • Guardant Health
    • PERSONALIS, INC.
    • FOUNDATION MEDICINE, INC.
    • Natera, Inc.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd
    • Menarini Silicon Biosystems, Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN
    • Bio-Rad Laboratories, Inc.
Product Code: FBI102506

Growth Factors of liquid biopsy Market

The global liquid biopsy market was valued at USD 11.66 billion in 2025 and is projected to grow to USD 14.23 billion in 2026, reaching a substantial USD 106.49 billion by 2034. The market is expected to expand at a compound annual growth rate (CAGR) of 28.61% during the forecast period. This rapid growth is primarily driven by the rising prevalence of cancer, increasing demand for non-invasive diagnostic techniques, and advancements in molecular diagnostics.

Liquid biopsy refers to the detection and analysis of circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cells, and biomarkers from biological fluids such as blood, cerebrospinal fluid, and amniotic fluid. These tests provide a minimally invasive alternative to traditional tissue biopsies for cancer diagnosis, prognosis, and therapy selection.

Market Size & Value (As per Report Year)

  • 2025 Market Size: USD 11.66 billion
  • 2026 Market Size: USD 14.23 billion
  • 2034 Forecast Market Size: USD 106.49 billion

Key Growth Drivers

The rising global burden of cancer is a major factor fueling market growth. According to ICMR data, cancer incidence in India increased from 1.39 million in 2020 to 1.46 million in 2022, reflecting a broader global trend. This surge has increased the demand for early screening, disease monitoring, and precision oncology solutions.

In addition, liquid biopsy plays a critical role in non-invasive prenatal testing (NIPT), driven by the increasing prevalence of chromosomal abnormalities such as Down syndrome. Government-supported screening initiatives and growing awareness of early disease detection have further boosted adoption.

Regulatory approvals from agencies such as the U.S. FDA for advanced cancer detection assays, along with continuous clinical research and innovation, are significantly supporting market expansion.

Market Restraints

Despite its advantages, the market faces challenges related to high test costs and reimbursement limitations. In the U.S., liquid biopsy tests can cost over USD 2,000 per test, making them less accessible for routine screening. Additionally, reimbursement restrictions-especially for early-stage cancer screening-limit broader adoption, particularly in developing economies such as India and China.

Segmentation Analysis

By Product:

Kits & reagents dominate the market, accounting for 80.08% share in 2026, due to frequent product launches and approvals for ctDNA and NIPT assays. Instruments are expected to grow at a moderate pace, supported by technological advancements in PCR and NGS platforms.

By Application:

Non-invasive prenatal testing (NIPT) held the largest share at 68.69% in 2026, driven by rising prenatal screening demand. The oncology segment is expected to grow at a higher CAGR, supported by increasing use in cancer diagnosis, therapy monitoring, and recurrence detection.

By End User:

Hospitals dominated the market with a 75.01% share in 2026, owing to high patient footfall and increasing adoption of cancer and prenatal tests. Clinical laboratories are expected to register notable growth due to expanding diagnostic infrastructure.

Regional Insights

North America dominated the global liquid biopsy market with a 54.57% share in 2025, driven by strong R&D investment, early adoption of precision oncology, and favorable reimbursement frameworks.

Europe follows due to government-led cancer screening programs and rising funding for diagnostic innovation.

Asia Pacific is expected to witness the fastest growth, supported by rising cancer prevalence, expanding healthcare access, and growing adoption of NIPT in countries such as China, Japan, and India.

Competitive Landscape

Key players include Guardant Health, Foundation Medicine, Natera, Illumina, Roche, Thermo Fisher Scientific, QIAGEN, and Bio-Rad Laboratories. Companies are focusing on strategic collaborations, clinical trials, and product innovations to strengthen their market presence.

Conclusion

The global liquid biopsy market is poised for strong long-term growth, expanding from USD 11.66 billion in 2025 to USD 106.49 billion by 2034. Rising cancer incidence, increasing preference for non-invasive diagnostics, and advancements in molecular testing technologies are the key growth catalysts. Although high costs and reimbursement challenges remain, continuous innovation, regulatory approvals, and expanding clinical applications are expected to drive widespread adoption, positioning liquid biopsy as a cornerstone of future precision medicine.

Growth Rate CAGR of 28.61% from 2026-2034

Segmentation By Product

  • Kits & Reagents
  • Instruments

By Application

  • Non-invasive Prenatal Testing (NIPT)
  • Oncology
  • Others

By End User

  • Hospitals
  • Clinical Laboratories
  • Others

By Region

  • North America (By Product, By Application, By End User, and By Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Product, By Application, By End User, and By Country/ Sub-region)
    • Germany (By Application)
    • U.K. (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Product, By Application, By End User, and By Country/ Sub-region)
    • Japan (By Application)
    • China (By Application)
    • India (By Application)
    • Australia (By Application)
    • Southeast Asia (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Product, By Application, By End User, and By Country/ Sub-region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Product, By Application, By End User, and By Country/ Sub-region)
    • GCC (By Application)
    • South Africa (By Application)
    • Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cancer, By Key Countries, 2025
  • 4.2. Key Industry Developments - Mergers, Partnerships, & Acquisitions
  • 4.3. New Product Launches, By Key Players
  • 4.4. Impact of COVID-19 on the Market

5. Global Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Kits & Reagents
    • 5.1.2. Instruments
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Non-invasive Prenatal Testing (NIPT)
    • 5.2.2. Oncology
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals
    • 5.3.2. Clinical Laboratories
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East and Africa

6. North America Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Kits & Reagents
    • 6.1.2. Instruments
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Non-invasive Prenatal Testing (NIPT)
    • 6.2.2. Oncology
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals
    • 6.3.2. Clinical Laboratories
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Application
    • 6.4.2. Canada
      • 6.4.2.1. By Application

7. Europe Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Kits & Reagents
    • 7.1.2. Instruments
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Non-invasive Prenatal Testing (NIPT)
    • 7.2.2. Oncology
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals
    • 7.3.2. Clinical Laboratories
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
      • 7.4.1.1. By Application
    • 7.4.2. Germany
      • 7.4.2.1. By Application
    • 7.4.3. France
      • 7.4.3.1. By Application
    • 7.4.4. Spain
      • 7.4.4.1. By Application
    • 7.4.5. Italy
      • 7.4.5.1. By Application
    • 7.4.6. Rest of Europe
      • 7.4.6.1. By Application

8. Asia Pacific Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Kits & Reagents
    • 8.1.2. Instruments
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Non-invasive Prenatal Testing (NIPT)
    • 8.2.2. Oncology
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals
    • 8.3.2. Clinical Laboratories
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Application
    • 8.4.2. China
      • 8.4.2.1. By Application
    • 8.4.3. India
      • 8.4.3.1. By Application
    • 8.4.4. Australia
      • 8.4.4.1. By Application
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Application
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Application

9. Latin America Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Kits & Reagents
    • 9.1.2. Instruments
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Non-invasive Prenatal Testing (NIPT)
    • 9.2.2. Oncology
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals
    • 9.3.2. Clinical Laboratories
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Application
    • 9.4.2. Mexico
      • 9.4.2.1. By Application
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Application

10. Middle East & Africa Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Kits & Reagents
    • 10.1.2. Instruments
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Non-invasive Prenatal Testing (NIPT)
    • 10.2.2. Oncology
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals
    • 10.3.2. Clinical Laboratories
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Application
    • 10.4.2. South Africa
      • 10.4.2.1. By Application
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Application

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Guardant Health
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. PERSONALIS, INC.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. FOUNDATION MEDICINE, INC.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Natera, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Illumina, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. F. Hoffmann-La Roche Ltd
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Menarini Silicon Biosystems, Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Thermo Fisher Scientific Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. QIAGEN
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Bio-Rad Laboratories, Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 01: Global Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 02: Global Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 03: Global Liquid Biopsy Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 04: Global Liquid Biopsy Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 05: North America Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 06: North America Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 07: North America Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 08: North America Liquid Biopsy Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 09: U.S. Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 10: Canada Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 12: Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 13: Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 14: Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 15: Germany Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 16: Spain Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 17: France Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 18: Italy Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 19: U.K. Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 20: Rest of Europe Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 21: Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 22: Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 23: Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 24: Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: China Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 26: India Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 27: Japan Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 28: Australia Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 29: Southeast Asia Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 30: Rest of Asia Pacific Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 31: Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 32: Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 33: Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 34: Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 35: Brazil Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 36: Mexico Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 37: Rest of Latin America Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 38: Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 39: Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 40: Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By End User 2021-2034
  • Table 41: Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 42: GCC Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 43: South Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 44: Rest of Middle East & Africa Liquid Biopsy Market Revenue (USD billion) Forecast, By Application, 2021-2034

List of Figures

  • Figure 01: Global Liquid Biopsy Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Liquid Biopsy Market Value Share (%), By Product, 2025 & 2034
  • Figure 03: Global Liquid Biopsy Market Value Share (%), By Application, 2025 & 2034
  • Figure 04: Global Liquid Biopsy Market Value Share (%), By End User, 2025 & 2034
  • Figure 05: Global Liquid Biopsy Market Value Share (%), By Region, 2025 & 2034
  • Figure 06: North America Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 07: North America Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 08: North America Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 09: North America Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 10: North America Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 11: North America Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 12: North America Liquid Biopsy Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Liquid Biopsy Market Value Share (%), by Country, 2025
  • Figure 14: Europe Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 15: Europe Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 16: Europe Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 17: Europe Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 18: Europe Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 19: Europe Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 20: Europe Liquid Biopsy Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Liquid Biopsy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 23: Asia Pacific Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 24: Asia Pacific Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 25: Asia Pacific Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 26: Asia Pacific Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Liquid Biopsy Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Liquid Biopsy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 31: Latin America Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 32: Latin America Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 33: Latin America Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 34: Latin America Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 35: Latin America Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 36: Latin America Liquid Biopsy Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Liquid Biopsy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Liquid Biopsy Market Value (USD billion), By Product, 2025 & 2034
  • Figure 39: Middle East & Africa Liquid Biopsy Market Value Share (%), By Product, 2025
  • Figure 40: Middle East & Africa Liquid Biopsy Market Value (USD billion), By Application, 2025 & 2034
  • Figure 41: Middle East & Africa Liquid Biopsy Market Value Share (%), By Application, 2025
  • Figure 42: Middle East & Africa Liquid Biopsy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 43: Middle East & Africa Liquid Biopsy Market Value Share (%), by End User, 2025
  • Figure 44: Middle East & Africa Liquid Biopsy Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Liquid Biopsy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Liquid Biopsy Market Share (%), 2025